• Natalia Pérez de la Ossa, Sònia Abilleira, Tudor G Jovin, Álvaro García-Tornel, Xavier Jimenez, Xabier Urra, Pere Cardona, Dolores Cocho, Francisco Purroy, Joaquin Serena, Luis San Román Manzanera, Rosa Maria Vivanco-Hidalgo, Mercè Salvat-Plana, Angel Chamorro, Miquel Gallofré, Carlos A Molina, Erik Cobo, Antoni Davalos, Marc Ribo, and RACECAT Trial Investigators.
• Department of Neurology, Stroke Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
• JAMA. 2022 May 10; 327 (18): 178217941782-1794.

ImportanceIn nonurban areas with limited access to thrombectomy-capable centers, optimal prehospital transport strategies in patients with suspected large-vessel occlusion stroke are unknown.ObjectiveTo determine whether, in nonurban areas, direct transport to a thrombectomy-capable center is beneficial compared with transport to the closest local stroke center.Design, Setting, And ParticipantsMulticenter, population-based, cluster-randomized trial including 1401 patients with suspected acute large-vessel occlusion stroke attended by emergency medical services in areas where the closest local stroke center was not capable of performing thrombectomy in Catalonia, Spain, between March 2017 and June 2020. The date of final follow-up was September 2020.InterventionsTransportation to a thrombectomy-capable center (n = 688) or the closest local stroke center (n = 713).Main Outcomes And MeasuresThe primary outcome was disability at 90 days based on the modified Rankin Scale (mRS; scores range from 0 [no symptoms] to 6 [death]) in the target population of patients with ischemic stroke. There were 11 secondary outcomes, including rate of intravenous tissue plasminogen activator administration and thrombectomy in the target population and 90-day mortality in the safety population of all randomized patients.ResultsEnrollment was halted for futility following a second interim analysis. The 1401 enrolled patients were included in the safety analysis, of whom 1369 (98%) consented to participate and were included in the as-randomized analysis (56% men; median age, 75 [IQR, 65-83] years; median National Institutes of Health Stroke Scale score, 17 [IQR, 11-21]); 949 (69%) comprised the target ischemic stroke population included in the primary analysis. For the primary outcome in the target population, median mRS score was 3 (IQR, 2-5) vs 3 (IQR, 2-5) (adjusted common odds ratio [OR], 1.03; 95% CI, 0.82-1.29). Of 11 reported secondary outcomes, 8 showed no significant difference. Compared with patients first transported to local stroke centers, patients directly transported to thrombectomy-capable centers had significantly lower odds of receiving intravenous tissue plasminogen activator (in the target population, 229/482 [47.5%] vs 282/467 [60.4%]; OR, 0.59; 95% CI, 0.45-0.76) and significantly higher odds of receiving thrombectomy (in the target population, 235/482 [48.8%] vs 184/467 [39.4%]; OR, 1.46; 95% CI, 1.13-1.89). Mortality at 90 days in the safety population was not significantly different between groups (188/688 [27.3%] vs 194/713 [27.2%]; adjusted hazard ratio, 0.97; 95% CI, 0.79-1.18).Conclusions And RelevanceIn nonurban areas in Catalonia, Spain, there was no significant difference in 90-day neurological outcomes between transportation to a local stroke center vs a thrombectomy-capable referral center in patients with suspected large-vessel occlusion stroke. These findings require replication in other settings.Trial RegistrationClinicalTrials.gov Identifier: NCT02795962.

43 keywords...

hide…